Wang Mingxing, Sun Qingming, Dong Wanhui
Department of Medical Oncology, Lu'an Hospital of Traditional Chinese Medicine Affiliated To Anhui University of Chinese Medicine, Lu'an, China.
Front Oncol. 2024 Nov 29;14:1498253. doi: 10.3389/fonc.2024.1498253. eCollection 2024.
Tislelizumab, as a PD-1 inhibitor, has demonstrated significant efficacy in cancer treatment. However, it may also induce immune-related adverse events (irAEs). This case report describes a patient who developed oral ulcers and dysphagia following treatment with tislelizumab, which was diagnosed as exfoliative esophagitis through endoscopic examination. The condition improved after corticosteroid pulse therapy. A review of the relevant literature revealed no prior reports of immune checkpoint inhibitor (ICI)-related esophagitis cases, prompting an exploration of the potential pathophysiological mechanisms and therapeutic strategies. This report emphasizes the importance of vigilance for rare irAEs during ICI therapy, advocating for early detection and timely intervention.
替雷利珠单抗作为一种程序性死亡受体-1（PD-1）抑制剂，已在癌症治疗中显示出显著疗效。然而，它也可能引发免疫相关不良事件（irAEs）。本病例报告描述了一名患者在接受替雷利珠单抗治疗后出现口腔溃疡和吞咽困难，经内镜检查诊断为剥脱性食管炎。经皮质类固醇冲击治疗后病情好转。对相关文献的回顾显示，此前尚无免疫检查点抑制剂（ICI）相关食管炎病例的报告，这促使我们探索潜在的病理生理机制和治疗策略。本报告强调了在ICI治疗期间对罕见irAEs保持警惕的重要性，提倡早期发现和及时干预。
